已发表论文

一例携带有新的 SLC34A2-ROS1  融合变异肺腺癌患者对克唑替尼 (crizotinib) 响应

 

Authors Zhao Z, Song ZJ, Wang XW, Sun HF, Yang XM, Yuan Y, Yu P

Received 6 March 2017

Accepted for publication 13 June 2017

Published 21 August 2017 Volume 2017:10 Pages 4129—4133

DOI https://doi.org/10.2147/OTT.S136297

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Tohru Yamada

摘要:ROS1  融合在非小细胞肺癌中是一种常见的基因变异。克唑替尼是一种间变性淋巴瘤激酶抑制剂,已经被证明在对携带有 ROS1  融合的肺癌的案例中有效。本文报道了一例携带有不同于常见的两种 SLC34A2-ROS1  融合变异类型的新变异患者同样对克唑替尼有效的案例。按照克唑替尼的说明书服药后,这名患者的身体总体好转;主要病变缩小;淋巴结转移消失;新陈代谢也恢复正常。
关键词:SLC34A2-ROS1  融合;克唑替尼;肺腺癌;二代测序

 


摘要视频链接Crizotinib treatment in lung adenocarcinoma patient with ROS1 fusion